Pivotal bioVenture Partners | Activity | F4Pivotal bioVenture Partners Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Milestone
Portfolio companies MapLight Therapeutics and Evommune completed successful IPOs.
MapLight Therapeutics and Evommune IPOs
Sanofi completed its acquisition of portfolio company Vigil Neuroscience.
Vigil Neuroscience acquired by Sanofi
Milestone
Portfolio company MapLight Therapeutics announced a $372.5M Series D financing.
MapLight Therapeutics $372.5M Series D
Milestone
Portfolio company Avalyn Pharma completed an oversubscribed $100M Series D.
Avalyn Pharma $100M Series D
3 exits· NOV 2024 – JUL 2025Show all
Exit
BioMarin completed its acquisition of portfolio company Inozyme Pharma.
Inozyme Pharma acquired by BioMarin
Exit
Novartis completed its acquisition of portfolio company Anthos Therapeutics in a deal worth up to $3.1B, $925M upfront.
Anthos Therapeutics acquired by Novartis
Exit
Portfolio company Exscientia officially combined with Recursion.
Exscientia combined with Recursion
Milestone
Portfolio company Evommune announced a $115M Series C financing.
Evommune $115M Series C
Exit
AstraZeneca announced it would acquire portfolio company Fusion Pharmaceuticals.
Fusion Pharmaceuticals acquired by AstraZeneca
New Fund
Closed Fund II at $389M, bringing total bioVenture commitments to $689M.
Pivotal bioVenture Partners Fund II